ADC Therapeutics SA, a clinical-stage oncology-focused biotech focused on the development and commercialization of highly potent antibody drug conjugates (ADCs) for patients suffering from hematological malignancies and solid tumors, has named Jennifer Creel as chief financial officer. Ms. Creel joins ADC Therapeutics from Celgene.
 
“I’m delighted to welcome Jenn to our senior leadership team,” said Chris Martin, chief executive officer, ADC Therapeutics. “Jenn has a track record of successfully establishing financial infrastructure, building commercial organizations and providing strategic financial direction for global biopharmaceutical companies and oncology franchises. Her expertise will be invaluable as we prepare to submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration for Lonca for the treatment of relapsed or refractory diffuse large B-cell lymphoma in the third quarter of 2020 and continue to build out our commercial organization in anticipation of a U.S. launch in mid-2021.”
 
Ms. Creel most recently served as franchise chief financial officer and corporate vice president, global finance and business planning at Celgene until its acquisition by Bristol Myers Squibb. During her 11 years at Celgene, Ms. Creel held multiple finance positions of increasing responsibility, including vice president of finance, hematology and oncology, and executive director, global business planning and analysis.